Yes, most clinical trials pay participants for their time, and the amounts range widely. Healthy volunteers in early-phase drug studies earn a median of about $3,070 per trial, with payments spanning from $150 for a simple vaccine study up to $13,000 for a 34-day residential stay. What you actually take home depends on the type of trial, how long it lasts, and how much it asks of you.
How Much Clinical Trials Typically Pay
The biggest factor in payment is the length and intensity of the study. A short outpatient visit where you answer questionnaires or give a blood sample might pay a few hundred dollars total. A Phase 1 trial that requires you to stay overnight in a research clinic for weeks will pay several thousand. In a large analysis of Phase 1 healthy volunteer trials, 65% offered less than $4,000, and fewer than 2% topped $10,000.
Phase 1 trials, where healthy people test a new drug for the first time, consistently pay more than later-phase trials. That’s because participants are taking on risk with no chance of personal medical benefit. Later-phase trials (Phase 2 and 3) enroll people who actually have the condition being studied, so the treatment itself is part of the value. These trials still often pay, but the amounts tend to be lower, sometimes covering only time and travel rather than offering a substantial stipend.
Inpatient studies, where you live at the research facility for days or weeks, sit at the high end of the pay scale. The logic is straightforward: you’re giving up your normal life, sleeping in a clinic bed, eating controlled meals, and submitting to frequent blood draws and monitoring. That level of commitment commands higher compensation. Outpatient studies that require periodic clinic visits over weeks or months typically pay per visit, with each visit earning anywhere from $25 to a few hundred dollars depending on what’s involved.
How Payments Are Structured
Clinical trial payments aren’t a single lump sum handed to you at the end. The FDA requires that payment accrue as the study progresses rather than being contingent on completing every last visit. This is an important protection: if you decide to withdraw halfway through, you should still receive pay for the portion you completed. Studies may hold back a small completion bonus as an incentive to finish, but it can’t be so large that it pressures you to stay in a trial you want to leave.
In practice, most studies pay per visit or per study phase. You might receive a check, direct deposit, or a reloadable debit card after each appointment. Some sites process payments in batches, so there can be a delay of a few weeks between your visit and receiving funds.
Travel costs are handled separately from participation payments. Reimbursement for parking, mileage, airfare, meals, and lodging is standard and treated differently from your stipend in both ethical and tax terms.
Not Every Trial Pays the Same Way
Some trials don’t pay a stipend at all. Large cancer trials, for example, sometimes offer only travel reimbursement because access to an experimental treatment is considered the primary draw for participants. Observational studies that simply track your health over time may pay modestly or not at all. Survey-based research might offer a gift card worth $20 to $50.
On the other end, pharmaceutical companies running early drug safety trials at dedicated research units are the highest payers. These facilities recruit healthy volunteers (often called “guinea pigs” informally) who have no medical reason to participate. The payment compensates for time, inconvenience, discomfort, and the inherent uncertainty of testing a new compound in humans for the first time.
Taxes on Clinical Trial Payments
Clinical trial payments count as taxable income. Starting in January 2026, the NIH will be required to report payments of $2,000 or more in a calendar year to the IRS. If you hit that threshold, you’ll receive a Form 1099 for miscellaneous income, and a copy goes to the IRS as well.
Reimbursements for out-of-pocket expenses like parking, meals, and mileage are not taxable and don’t count toward the $2,000 reporting threshold. But the stipend portion, the money you receive for your time, is income in the eyes of the IRS regardless of whether you receive a 1099. Even below the reporting threshold, you’re technically supposed to report it.
Why Payments Have Ethical Limits
You might wonder why trials don’t simply pay more to attract participants faster. The answer is that ethics boards, called Institutional Review Boards (IRBs), review every study’s payment plan before a single participant enrolls. Their concern is “undue inducement,” the idea that an extremely large payment could cloud someone’s judgment about the risks involved. If a $20,000 offer tempts someone to ignore side effects or stay enrolled when their body is telling them to stop, that payment has crossed a line.
Federal guidelines require that compensation be “ethically appropriate, just, and fair.” IRBs evaluate whether the amount is reasonable for the time and discomfort involved without being so high that it overrides a person’s ability to make a clear-headed decision. They also review recruitment materials to make sure payment isn’t being emphasized in ways that could manipulate potential participants, like advertising the dollar amount in oversized bold text.
Payment Norms Outside the U.S.
Payment practices vary significantly by country. The U.S. has the most transparent system through the Sunshine Act, which requires drug and device companies to publicly disclose payments exceeding $10 made to physicians and teaching hospitals involved in research. Most European countries rely on industry self-regulation instead, with companies reporting research payments as lump sums without naming individual recipients. Only Denmark, France, Portugal, and a handful of other countries have enacted laws mandating public disclosure of at least some research-related payments.
In the UK and much of Europe, patient trials commonly reimburse expenses and offer modest stipends, but the culture around paying healthy volunteers varies. Some countries’ ethics boards are more conservative about cash payments, viewing them with greater suspicion as potential inducements. If you’re considering a trial outside the U.S., the payment terms should be clearly spelled out in the informed consent document before you agree to anything.
What Affects Your Total Earnings
Several factors determine where your payment falls on the spectrum:
- Study phase. Phase 1 trials with healthy volunteers pay the most. Phase 2 and 3 trials with patients pay less.
- Duration and confinement. Overnight stays and multi-week residential periods dramatically increase compensation.
- Number of visits. Outpatient studies that require 15 visits over six months pay more total than a single-visit study, though each visit may pay modestly.
- Procedures involved. Studies requiring biopsies, spinal taps, or repeated blood draws tend to compensate more than those involving only questionnaires.
- Your health status. Healthy volunteers in early drug trials are compensated for pure inconvenience and risk. Patients in later trials may receive less because the potential treatment benefit is part of the equation.
Payment details are always listed in the informed consent form and often in the study’s recruitment listing on sites like ClinicalTrials.gov. Before you enroll, you’ll know exactly what the study pays, when you’ll receive it, and what happens to your payment if you withdraw early.